Ireland
--:--IST
Recruiting Observational

LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice

NCT04733430 · tracked via the Priya Life Science Austria tracker
Sponsor
Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Phase
Observational
Started
2020-04-17
Last updated
2024-03-18

Condition(s) studied

Lung Cancer

Study summary

This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.

Eligibility

Sex
ALL
Min age
18 Years
Max age
125 Years
Healthy volunteers
No
Inclusion Criteria: * Informed consent * Histologically confirmed lung cancer * Age ≥ 18 years * Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments Exclusion Criteria: \-

Primary outcome measure(s)

  • NGS Testing — through study completion, an average of 5 years
    To assess molecular biomarker testing and indicators of the quality of care in patients with lung cancer

Trial sites (1)

FacilityCityRegionStatus
Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie Vienna Austria Recruiting

More Karl Landsteiner Institute for Lung Research and Pneumological Oncology trials in Austria

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04733430 on ClinicalTrials.gov ↗ ← All trials in Austria